ShopResearchQualityLab ResultsPartner
Log In

Research Guides

Long-form research guides on peptide reconstitution, dosing protocols, sourcing and compound comparisons, written for laboratory research use.

All Guides

7 guides
Research Guide

KLOW Peptide Blend: Complete Research Guide to KPV, GHK-Cu, BPC-157 and TB-500

KLOW is a four-peptide research blend containing KPV (Lys-Pro-Val), GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157) and TB-500 (synthetic Thymosin β-4). It is the four-component evolution of the three-peptide GLOW stack, and the addition is KPV. Each component acts on a different part of the tissue-repair cascade — NF-κB inflammatory signalling, extracellular matrix remodelling, local VEGF-mediated angiogenesis, and systemic actin-mediated cell migration respectively. All material is supplied for in-vitro laboratory research use only.

Updated

Research Guide

GLOW vs KLOW Peptide Blend: Composition, Mechanisms and Research Differences

GLOW and KLOW are the same regenerative research formulation with one difference: KLOW contains KPV. GLOW is a three-peptide blend of GHK-Cu, BPC-157 and TB-500. KLOW is those same three peptides plus KPV (Lys-Pro-Val, C16H30N4O4, 342.4 Da, CAS 67727-97-3), the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone, which contributes NF-κB-directed anti-inflammatory activity and gut-barrier research relevance. No published study has compared the two formulations head to head, so the incremental contribution of KPV is inferred from single-compound literature rather than measured directly.

Updated

Research Guide

KLOW Peptide Research Protocol: 80mg Vial Reconstitution and Concentration Guide

Reconstitution concentration for a KLOW vial is arithmetic, not a protocol: concentration (mg/mL) equals peptide mass (mg) divided by diluent volume (mL). For the standard 80 mg KLOW vial, 2 mL of bacteriostatic water yields 40 mg/mL, 2.5 mL yields 32 mg/mL, 3 mL yields 26.67 mg/mL, and 4 mL yields 20 mg/mL — all expressed as total blend mass, not as the concentration of any single peptide. Per-component concentration requires the compositional ratio printed on the batch Certificate of Analysis. Peptide.Express publishes no administration protocol or frequency chart for KLOW because no pharmacokinetic data exists for this four-peptide blend and the compounds are supplied as in-vitro research materials only.

Updated

Research Guide

BPC-157 + TB-500 Wolverine Stack: Complementary Mechanisms in Tissue Repair Research

BPC-157 and TB-500 are studied together because their mechanisms are complementary rather than redundant. BPC-157 (15 amino acids, GEPPPGKPADDAGLV, C62H98N16O22, 1,419.5 Da, CAS 137525-51-0) upregulates VEGF to drive local angiogenesis and activates focal adhesion kinase and paxillin at the site where it is placed. TB-500 (synthetic Thymosin β-4, 4,963.4 Da, CAS 77591-33-4, carrying the LKKTET actin-binding motif) sequesters monomeric G-actin, enabling systemic cell migration toward that site. Local activation and systemic recruitment are sequential steps of a single repair cascade, which is the pharmacological argument for the combination — though no published pharmacokinetic study of the two compounds administered together exists.

Updated

Research Guide

GHK-Cu Copper Peptide: Research Guide to Collagen Synthesis, Tissue Remodeling and Anti-Aging Studies

GHK-Cu is glycyl-L-histidyl-L-lysine coordinated with a copper(II) ion — molecular formula C14H24CuN6O4, molecular weight 403.9 Da as the copper complex against 340.4 Da for the free tripeptide. In cell-culture models it signals dermal fibroblasts to upregulate Type I and Type III collagen through TGF-β modulation while simultaneously activating matrix metalloproteinases 1, 2 and 9, so the net effect studied is matrix turnover rather than matrix accumulation. A second, mechanistically separate arm delivers bioavailable copper to lysyl oxidase, the enzyme that crosslinks collagen and elastin fibrils. GHK-Cu is not FDA-approved for human therapeutic use and is supplied for in-vitro laboratory research only.

Updated

Research Guide

Tesamorelin Research Guide: GHRH Analog Mechanism, IGF-1 Signaling and Laboratory Protocols

Tesamorelin is a stabilized 44-amino-acid analog of growth hormone-releasing hormone — molecular formula C221H366N72O67S, molecular weight 5,135.9 Da, CAS 218949-48-5 — carrying a trans-3-hexenoyl modification at the N-terminus that blocks the dipeptidyl peptidase IV cleavage which destroys native GHRH within minutes. It binds GHRH-R on anterior pituitary somatotrophs, driving pulsatile endogenous growth hormone release that preserves hypothalamic somatostatin feedback, which exogenous HGH suppresses. Downstream, GH drives hepatic IGF-1 production and increases lipolytic tone with reported selectivity for visceral over subcutaneous adipose depots. Tesamorelin holds an FDA approval as the drug product Egrifta for HIV-associated lipodystrophy; that approval covers the pharmaceutical, not research-market material, which is supplied for in-vitro laboratory research only.

Updated

Research Guide

Research Peptides USA: A Sourcing Guide to HPLC-Verified Laboratory-Grade Compounds

Evaluating a research peptide supplier comes down to four documents and one question each. HPLC purity tells you what proportion of the material is the target peptide by area under the curve — it does not tell you what the remainder is. LC-MS/MS tells you the molecular identity, which is the only reliable way to know that the powder in the vial is the molecule on the label. LAL endotoxin testing measures bacterial endotoxin load, not sterility. And a batch-specific Certificate of Analysis ties all three to the lot number printed on the vial, which is what makes a result reproducible. Most compounds sold on this market are not FDA-approved for human use, several are WADA-prohibited, and research-market material is not manufactured under pharmaceutical GMP.

Updated

Continue Researching